Partnerships

“Partnering with Renew gives our customers more flexibility in how they access advanced sequencing. By combining SureSelect enrichment with Renew’s sequencing technology and send-out service, customers can generate high-quality sequencing data without having to bring a new workflow in-house.”

Nina Green · VP Clinical Diagnostics · Agilent Technologies

Renew develops sequencing technologies and products to support better clinical decisions, but their impact depends on reaching the providers, patients, and care settings they were built for.

By partnering with organizations that understand markets, channels, and clinical communities, Renew helps move new technologies from development into adoption, bringing advanced molecular insights to the providers and patients they were designed to serve.

“Renew has been instrumental in helping us generate high-quality, multiomic datasets. Their integrated sequencing, laboratory, and bioinformatics capabilities have given us greater confidence in the biological signals within our data and allowed us to progress our models to the next stage of development.”

Joshua Pacini · CEO & Co-Founder · Valinor

Native-read and long-read sequencing reveal biology that standard methods often miss, but realizing that potential requires more than sequencing alone. 

Renew builds the protocols, analytical infrastructure, validation frameworks, and clinical laboratory systems that give assay development a stronger foundation from concept through deployment.

Biopharma and translational teams often need more than standard sequencing results. They need molecular context to better understand disease biology and guide development decisions.

Renew supports biomarker discovery, patient stratification, therapy monitoring, mechanism-of-action studies, and clinical development through advanced sequencing approaches that generate actionable molecular insights.